Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diabetic Ketoacidosis Clear all
Terminated Phase 2 Interventional

Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis

NCT06007508
View directory record Official record
Conditions
DKA
Interventions
Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA

NCT00920725
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Insulin (Aspart Insulin [Novolog], Regular Insulin)
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 24, 2026, 4:03 PM EDT
Withdrawn Phase 2 Interventional

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

NCT01477476
View directory record Official record
Conditions
Type I Diabetes
Interventions
Anakinra, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Withdrawn Not applicable Interventional

Continuous Glucose Monitoring Using a New Subcutaneous Insulin Protocol for Mild to Moderate Diabetic Ketoacidosis

NCT06693115
View directory record Official record
Conditions
Diabetic Ketoacidosis, Hyperglycemia
Interventions
CGM with alerts
Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

StatStrip Glucose/Ketone Meter System Ketone Evaluation

NCT05118061
View directory record Official record
Conditions
Diabetes Mellitus, Ketosis, Diabetic
Interventions
Ketone
Diagnostic Test
Lead sponsor
Nova Biomedical
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Medley, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 4 Interventional

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

NCT06699810
View directory record Official record
Conditions
Ketosis Prone Diabetes
Interventions
Continuous Glucose Monitoring, Insulin
Device · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

NCT02930044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Early administration of subcutaneous insulin glargine dose, IV insulin infusion, IV fluid repletion
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Remote Glucose Monitoring System in Hospitalized Patients With Diabetic Ketoacidosis (DKA)

NCT05439928
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
DEXCOM G6 CGM
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

NCT03107208
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes Mellitus
Interventions
Glargine, Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational

Compliance With American Diabetes Association Treatment Guidelines for Adult Ketoacidosis

NCT00589680
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Not listed
Lead sponsor
Marshall University
Other
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Huntington, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Degludec, Standard long-acting
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients

NCT02950181
View directory record Official record
Conditions
Stroke, Diabetic Ketoacidosis, Increased Intracranial Pressures, Altered Mental Status
Interventions
NIRS
Device
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Day to 21 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

NCT02962492
View directory record Official record
Conditions
Evaluate Ketogenic Stress
Interventions
Exenatide/Exenatide extended release, Dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Results available

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

NCT00590044
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
insulin glargine+ glulisine, NPH + Regular insulin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Atlanta, Georgia • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors

NCT07421518
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
SGLT-2 inhibitor (Sotagliflozin), Insulin withdrawal test (IWT)
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Early Phase 1 Interventional

FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults With Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis

NCT06114186
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
FAM intervention consisting of a Follower of glucose data, Action Plan, and Remote Monitoring of glucose data, standard of care
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ketosis Prone Diabetes in African-Americans

NCT00426413
View directory record Official record
Conditions
Ketosis Prone Diabetes, Diabetic Ketoacidosis, Severe Hyperglycemia
Interventions
pioglitazone
Drug
Lead sponsor
Emory University
Other
Eligibility
19 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional

Fluid Resuscitation for Pediatric Diabetic Ketoacidosis

NCT01701557
View directory record Official record
Conditions
Diabetes
Interventions
slow fluid rate, fast fluid rate
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Sep 24, 2026, 4:03 PM EDT
Not yet recruiting Phase 2 Interventional

Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.

NCT07325201
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
Interventions
Sotagliflozin initiation
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Not applicable Interventional Results available

Two Bag System for Diabetic Ketoacidosis

NCT03660189
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Two bag system
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis

NCT01365793
View directory record Official record
Conditions
Cerebral Edema, Diabetic Ketoacidosis
Interventions
0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
1,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

NCT00732524
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glipizide, Glipizide and Glargine
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 11, 2008 · Synced Sep 24, 2026, 4:03 PM EDT